Decline in Cardiovascular Mortality: Framingham 1950-1984

This study has been completed.
Sponsor:
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00005222
First received: May 25, 2000
Last updated: June 23, 2005
Last verified: April 2000
  Purpose

To investigate possible mechanisms responsible for the decline in cardiovascular disease mortality among the Framingham Heart Study population and to evaluate the health status of survivors in terms of subsequent illness and functional limitations.


Condition
Cardiovascular Diseases
Coronary Disease
Hypertension
Heart Diseases

Study Type: Observational
Study Design: Observational Model: Natural History

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: April 1988
Estimated Study Completion Date: March 1996
Detailed Description:

BACKGROUND:

Cardiovascular disease mortality has declined more than 30 percent in the last thirty years. Almost two-thirds of this decline occurred between 1970 and 1980. Despite this decreased mortality, cardiovascular disease is still the leading cause of death. It is also the disease category associated with the most rapidly rising health care costs. Secular trends in lifestyle, self-care, improved access to medical care, and improvements in diagnostic and curative medicine have all been implicated. An understanding of the mechanisms contributing to this decline is necessary in order to develop a scientific basis for palliative and preventive care. Also, the dramatic decline in cardiovascular disease mortality has raised the issue of the quality of life among the survivors. The question is raised whether more people are surviving but with worsening health in terms of increased incidence and prevalence of disease as well as increased levels of functional limitation.

DESIGN NARRATIVE:

Five hypotheses were tested to address the issue of secular trends in lifestyle, self-care and medical care which may have influenced cardiovascular disease mortality. These were: differences in risk factor levels among similarly-aged birth cohorts influenced mortality by lessening the severity of disease or by improving recuperative capacity; mortality among the later birth cohorts declined due to less comorbid disease at the time of the disease event; long-term case fatality declined because the progression of disease was slower as evidenced by a reduction in disease recurrence; medical intervention reduced mortality by eliminating lethal sequelae in the later birth cohorts; decreased mortality resulted from medical innovations in diagnosis and therapy. Three hypotheses were tested to address the issue of worsening health among the survivors in the later birth cohorts. These were: although more individuals in the later birth cohorts survived 13 years of follow-up than did members of similarly-aged birth cohorts in earlier periods, they had higher rates of morbidity and were hospitalized more often; survivors in the later cohorts exhibited more disability in functional limitations; more survivors in the later cohorts were institutionalized in chronic care hospitals or skilled nursing facilities. Data on risk factors, co-morbidity, and recurrent cardiovascular disease in the three birth cohorts were already computerized. Data on medical interventions, improvement in case management, and the use of various technological innovations were abstracted from medical records and linked with the data on disease events. Data on functional limitations were available both by type and extent of disability from the Disability Analysis of Health Data, a study supported by the Social Security Administration. This data file was merged with the file for disease events to determine if general differences in functional health existed among the three birth cohorts at intake, and if between-cohort differences existed among survivors.

The study was renewed as a Shannon Award in Fiscal 1991.

  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

No eligibility criteria

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00005222     History of Changes
Other Study ID Numbers: 1101
Study First Received: May 25, 2000
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cardiovascular Diseases
Heart Diseases
Hypertension
Coronary Disease
Coronary Artery Disease
Vascular Diseases
Myocardial Ischemia
Arteriosclerosis
Arterial Occlusive Diseases

ClinicalTrials.gov processed this record on September 22, 2014